New hope for liver disease: trial tests drug to control autoimmune hepatitis
NCT ID NCT06381453
Summary
This study is testing whether adding a drug called belimumab to standard treatment helps people with autoimmune hepatitis, a chronic liver disease. It aims to see if the combination can better control the disease and allow patients to reduce their use of steroid medications, which often have difficult side effects. The trial will enroll 48 adults in Canada who either have active disease or are in remission on current therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
G.I Research Institute
RECRUITINGVancouver, British Columbia, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
London Health Sciences Centre
RECRUITINGLondon, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
McMaster University
RECRUITINGHamilton, Ontario, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Calgary
RECRUITINGCalgary, Alberta, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.